<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-202 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-202</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-202</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-8.html">extraction-schema-8</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of specific brain cell types reported as most susceptible or most resilient in Alzheimer's disease, along with where and when this was observed, how it was measured, quantitative results, proposed mechanisms (including genetic risk enrichment), modifiers (e.g., sex, APOE), contradictions, and any causal/perturbational evidence.</div>
                <p><strong>Paper ID:</strong> paper-df4cf65ac1fc2a7bc7a7c6998c738639e43a684c</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/df4cf65ac1fc2a7bc7a7c6998c738639e43a684c" target="_blank">Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease</a></p>
                <p><strong>Paper Venue:</strong> Neurobiology of Disease</p>
                <p><strong>Paper TL;DR:</strong> The comparison of proteomic changes in brain regions affected by tau pathology at different stages of AD is provided, and it is found that the dysregulated processes are predominantly region specific.</p>
                <p><strong>Cost:</strong> 0.021</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e202.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e202.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of specific brain cell types reported as most susceptible or most resilient in Alzheimer's disease, along with where and when this was observed, how it was measured, quantitative results, proposed mechanisms (including genetic risk enrichment), modifiers (e.g., sex, APOE), contradictions, and any causal/perturbational evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Neuronal synapse (general neurons)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neuronal synaptic compartment / neurons (general, including excitatory synapses)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Bulk-proteomics evidence across four human cortical regions shows pervasive loss/down-regulation of synaptic proteins during AD progression, interpreted as synapse loss and neuronal/synaptic vulnerability.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cell_type_name</strong></td>
                            <td>Neurons (synaptic compartment)</td>
                        </tr>
                        <tr>
                            <td><strong>cell_subtype_or_state</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>cell_class</strong></td>
                            <td>excitatory/inhibitory neuron (general neuronal synapse compartment)</td>
                        </tr>
                        <tr>
                            <td><strong>markers_or_genes</strong></td>
                            <td>Multiple synaptic proteins measured by proteomics, e.g. VAMP2, SV2B, SYNGAP1, CAMK2A, BSN, RIMS1, SNAP-associated proteins (see Table 1 and Table S3-S5)</td>
                        </tr>
                        <tr>
                            <td><strong>brain_region_and_layer</strong></td>
                            <td>Entorhinal cortex (EC), Parahippocampal cortex (PHC) — medial temporal lobe (MTL); Temporal cortex (TC) and Frontal cortex (FC) — neocortex. No laminar detail provided.</td>
                        </tr>
                        <tr>
                            <td><strong>species_or_model</strong></td>
                            <td>Human postmortem AD tissue (pure AD cases; microdissected cortical micropunches)</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_or_braak</strong></td>
                            <td>Compared controls vs early B/B (I–III) and late B/B (IV–VI) stages (Braak/Braak tau staging)</td>
                        </tr>
                        <tr>
                            <td><strong>susceptibility_label</strong></td>
                            <td>susceptible</td>
                        </tr>
                        <tr>
                            <td><strong>measurement_type</strong></td>
                            <td>Bulk label-free LC-MS/MS proteomics (discovery) with targeted PRM verification for selected proteins</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_change</strong></td>
                            <td>Majority of synapse-related proteins down-regulated: >70% down-regulated in MTL clusters and >60% down-regulated in neocortex clusters; examples from Table 1: VAMP2 log2FC (late) = -1.377 (EC), SYNGAP1 log2FC (late PHC) = -0.642, BSN and RIMS1 show log2 decreases in neocortex late stages (-0.669 to -0.863 for BSN/RIMS1 in some comparisons). Total DEPs during progression: EC 248, PHC 278, TC 163, FC 171 (many are synaptic).</td>
                        </tr>
                        <tr>
                            <td><strong>pathology_measured</strong></td>
                            <td>Tau pathology stage (Braak), and Aβ peptide level (Aβ peptide measured by PRM; Aβ increased in each region during AD progression); synaptic protein abundance as proxy for synapse loss.</td>
                        </tr>
                        <tr>
                            <td><strong>associations_with_pathology</strong></td>
                            <td>Paper notes that synapse loss is an early event and correlates best with cognitive decline (cites prior literature) and that synaptic proteins were already altered in neocortex at early Braak stages—indicating dysfunction prior to insoluble tau deposition. No correlation coefficients (r/p) are reported in this dataset.</td>
                        </tr>
                        <tr>
                            <td><strong>spatial_or_proximity_context</strong></td>
                            <td>Regional (EC/PHC vs TC/FC) comparisons across sampled micropunches; no plaque/tangle proximity or laminar localization was measured in this proteomic study.</td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_hypothesis</strong></td>
                            <td>Synapse vulnerability is linked to (a) soluble tau and Aβ toxicity causing synaptic dysfunction, (b) impaired oxidative phosphorylation / mitochondrial dysfunction (especially in MTL), and (c) translation dysregulation (reduced ribosomal proteins) leading to impaired proteostasis required for synaptic maintenance.</td>
                        </tr>
                        <tr>
                            <td><strong>ad_gwas_gene_enrichment</strong></td>
                            <td>DEPs included proteins overlapping AD risk loci: 27 DEPs match AD risk genes (Hu et al., 2017); interactome shows APP as a central node and synaptic proteins are overrepresented among DEPs. No enrichment p-value for synaptic-cell-specific GWAS given.</td>
                        </tr>
                        <tr>
                            <td><strong>perturbation_or_causal_evidence</strong></td>
                            <td>This study is observational (human proteomics) and provides no direct perturbation experiments; authors cite causal/perturbational evidence from other studies: tauopathy mouse models where soluble tau causes presynaptic deficits (Yoshiyama et al., 2007; Polydoro et al., 2013) and Aβ oligomers causing synaptic degeneration (Walsh et al., 2002).</td>
                        </tr>
                        <tr>
                            <td><strong>modifiers_and_risk_factors</strong></td>
                            <td>APOE discussed as a regional modifier (higher APOE protein in MTL); study cohort had >70% APOE ε3 homozygotes so isoform effects not systematically tested here. Age and sex were unbalanced across groups and proteins significantly associated with age or sex were removed from DEP lists.</td>
                        </tr>
                        <tr>
                            <td><strong>comorbid_pathologies</strong></td>
                            <td>The cohort consisted of 'pure AD' brains (excluded significant coexisting non-AD pathologies such as FTLD-tau, PSP, CBD); therefore comorbid pathologies were minimized.</td>
                        </tr>
                        <tr>
                            <td><strong>comparisons_to_other_cell_types</strong></td>
                            <td>Direct contrast in proteome: synaptic/neuronal proteins down-regulated across regions vs astrocyte markers (GFAP, VIM, CD44) that are up-regulated (late-up clusters) — indicating opposite changes in neurons versus astroglial response.</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_or_null_findings</strong></td>
                            <td>Some proteins showed opposite directions across regions (13 proteins changed in opposite directions across comparisons). APP protein itself was constant or slightly decreased while Aβ peptide increased (apparent discordance between holo-APP and Aβ peptide measurements).</td>
                        </tr>
                        <tr>
                            <td><strong>replication_or_cross_cohort_validation</strong></td>
                            <td>Comparison with two independent proteomic studies (Hondius et al., 2016; Seyfried et al., 2017) found 275 overlapping DEPs between at least two studies and 24 common across all three; many synaptic proteins overlapped and showed concordant down-regulation. PRM targeted MS validated 16/17 selected DEPs in at least one region.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_and_counts</strong></td>
                            <td>103 tissue samples total from 4 brain regions (EC, PHC, TC, FC). DEPs during progression: EC 248, PHC 278, TC 163, FC 171. Proteins identified per region: EC 3809, PHC 3815, TC 3610, FC 3720 (protein groups with ≥2 peptides).</td>
                        </tr>
                        <tr>
                            <td><strong>dataset_or_platform</strong></td>
                            <td>Label-free discovery LC-MS/MS on Thermo Q Exactive (DDA) with Proteome Discoverer SEQUEST HT analysis; PRM verification on Thermo Q Exactive HF-X; data deposited PXD010138.</td>
                        </tr>
                        <tr>
                            <td><strong>functional_impact</strong></td>
                            <td>Authors interpret synaptic protein loss as synapse loss, an early AD hallmark that correlates with cognitive impairment; mitochondrial and translation deficits linked to energy failure and impaired protein synthesis, likely aggravating synaptic dysfunction.</td>
                        </tr>
                        <tr>
                            <td><strong>key_evidence_snippet</strong></td>
                            <td>"Changes in protein expression indicate that synapse loss occurred in all analyzed regions... The majority of altered proteins were found down-regulated in AD considering all regions (>70% in MTL and >60% in the neocortex)."</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease", 'publication_date_yy_mm': '2019-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e202.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e202.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of specific brain cell types reported as most susceptible or most resilient in Alzheimer's disease, along with where and when this was observed, how it was measured, quantitative results, proposed mechanisms (including genetic risk enrichment), modifiers (e.g., sex, APOE), contradictions, and any causal/perturbational evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Astrocytes (GFAP↑)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Astrocytes / reactive astrocytes (as indicated by GFAP up-regulation)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Proteomics shows increased abundance of astrocyte-associated proteins (notably GFAP) during AD progression in multiple cortical regions, consistent with astrocytosis/reactive astrocyte response.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cell_type_name</strong></td>
                            <td>Astrocyte (reactive astrocyte state inferred)</td>
                        </tr>
                        <tr>
                            <td><strong>cell_subtype_or_state</strong></td>
                            <td>reactive astrocyte (astrocyte development / astrocytosis enriched in late-up clusters)</td>
                        </tr>
                        <tr>
                            <td><strong>cell_class</strong></td>
                            <td>astrocyte</td>
                        </tr>
                        <tr>
                            <td><strong>markers_or_genes</strong></td>
                            <td>GFAP (glial fibrillary acidic protein) primary marker reported; VIM and CD44 also reported among up-regulated proteins; APOE protein measured and discussed in context of astrocyte biology.</td>
                        </tr>
                        <tr>
                            <td><strong>brain_region_and_layer</strong></td>
                            <td>Observed increases in EC (MTL), PHC (MTL) and FC (neocortex) — specific values reported for EC, PHC, FC; no laminar localization.</td>
                        </tr>
                        <tr>
                            <td><strong>species_or_model</strong></td>
                            <td>Human postmortem AD tissue</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_or_braak</strong></td>
                            <td>Reported increases during AD progression; GFAP log2 fold changes: early B/B EC = +0.771, late B/B EC = +1.212; late PHC = +0.914; FC early +0.893 and late +0.884 (see Table 1).</td>
                        </tr>
                        <tr>
                            <td><strong>susceptibility_label</strong></td>
                            <td>reactive / increased (not framed as 'resilient' but as an up-regulated reactive cell-type signature)</td>
                        </tr>
                        <tr>
                            <td><strong>measurement_type</strong></td>
                            <td>Bulk LC-MS/MS proteomics (discovery) with PRM verification for selected proteins</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_change</strong></td>
                            <td>GFAP increased: example log2 fold-changes from Table 1 — EC early +0.771, EC late +1.212; PHC late +0.914; FC early +0.893, FC late +0.884. Astrocyte-related GO terms (astrocyte development) enriched in late-up clusters.</td>
                        </tr>
                        <tr>
                            <td><strong>pathology_measured</strong></td>
                            <td>Tau Braak stage; GFAP increase is linked to reactive gliosis in the context of AD pathology; Aβ peptide levels were increased in all regions.</td>
                        </tr>
                        <tr>
                            <td><strong>associations_with_pathology</strong></td>
                            <td>Paper interprets GFAP up-regulation as part of late-up cluster and astrocyte development pathway enrichment in regions during AD progression; direct correlations (r/p) with tangle or plaque burden are not provided.</td>
                        </tr>
                        <tr>
                            <td><strong>spatial_or_proximity_context</strong></td>
                            <td>Regional increases (MTL and neocortex); no assessment of periplaque or laminar proximity in this proteomic dataset.</td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_hypothesis</strong></td>
                            <td>Authors discuss astrocyte involvement in metabolic regulation and APOE biology; higher APOE levels in MTL (likely astrocyte-related) may interact with Aβ/tau toxicity — APOE isoform effects on APP transcription and tau toxicity are cited as mechanisms linking astrocytes/APOE to vulnerability.</td>
                        </tr>
                        <tr>
                            <td><strong>ad_gwas_gene_enrichment</strong></td>
                            <td>APOE (major AD genetic risk factor) is among proteins measured and is higher in MTL; overall 27 DEPs correspond to AD risk loci. No cell-type-specific GWAS enrichment statistic given.</td>
                        </tr>
                        <tr>
                            <td><strong>perturbation_or_causal_evidence</strong></td>
                            <td>No perturbations in this study. Cited causal literature includes APOE ε4 exacerbating tau-mediated neurodegeneration (Shi et al., 2017) and APOE isoforms differentially stimulating APP transcription (Huang et al., 2017) — supportive of astrocyte/APOE contribution to pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>modifiers_and_risk_factors</strong></td>
                            <td>APOE genotype discussed as a major modifier (ε4 risk, ε2 protective); this cohort had >70% APOE ε3 homozygotes so limited isoform analysis. Age and sex imbalances existed and were controlled by removing age/sex-associated proteins from DEPs.</td>
                        </tr>
                        <tr>
                            <td><strong>comorbid_pathologies</strong></td>
                            <td>Pure AD cases were selected (excluded significant coexisting non-AD pathologies).</td>
                        </tr>
                        <tr>
                            <td><strong>comparisons_to_other_cell_types</strong></td>
                            <td>Astrocyte markers increased while neuronal/synaptic proteins decreased in the same regions, indicating divergent cellular responses; APOE higher in MTL (astrocyte-associated) compared to neocortex in controls.</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_or_null_findings</strong></td>
                            <td>Although APOE protein is higher in MTL in discovery data, statistical significance was limited (some pairwise comparisons only); the authors note limited ability to analyze APOE isoforms quantitatively due to genotype distribution.</td>
                        </tr>
                        <tr>
                            <td><strong>replication_or_cross_cohort_validation</strong></td>
                            <td>GFAP was among proteins found up-regulated in comparison with two other proteomic datasets; PRM validation confirmed GFAP differential expression in at least one region (16/17 DEPs validated in PRM assay).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_and_counts</strong></td>
                            <td>103 tissue samples total across 4 regions; DEPs per region as above. PRM panel included 75 peptides corresponding to 21 proteins and confirmed GFAP changes (see Table S9).</td>
                        </tr>
                        <tr>
                            <td><strong>dataset_or_platform</strong></td>
                            <td>Discovery LC-MS/MS on Thermo Q Exactive; PRM verification on Q Exactive HF-X; data PXD010138.</td>
                        </tr>
                        <tr>
                            <td><strong>functional_impact</strong></td>
                            <td>Astrocyte activation (astrocytosis) is interpreted as part of AD-associated inflammatory/repair responses and possibly linked to APOE-mediated modulation of Aβ and tau toxicity and regional metabolic regulation.</td>
                        </tr>
                        <tr>
                            <td><strong>key_evidence_snippet</strong></td>
                            <td>"The cluster with augmented expression levels in late disease stages consists of 3 proteins including two well-known AD players: filamin A (FLNA) and glial fibrillary acidic protein (GFAP), a marker of astrocytes..." and pathway analysis shows 'astrocyte development' enriched in late-up clusters.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease", 'publication_date_yy_mm': '2019-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e202.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e202.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of specific brain cell types reported as most susceptible or most resilient in Alzheimer's disease, along with where and when this was observed, how it was measured, quantitative results, proposed mechanisms (including genetic risk enrichment), modifiers (e.g., sex, APOE), contradictions, and any causal/perturbational evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Medial temporal lobe neurons (MTL vulnerability)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Medial temporal lobe principal neurons (inferred vulnerability of MTL neuronal population)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Proteomic signature of healthy MTL (EC + PHC) shows higher baseline expression of mitochondrial, ribosomal and translation/proteasome proteins and higher APOE levels, and these same components show pronounced down-regulation during AD — interpreted as a basis for MTL regional vulnerability (early tau pathology).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cell_type_name</strong></td>
                            <td>Medial temporal lobe neurons / neuronal population (principal neurons implicated by enriched synaptic/plasticity proteins)</td>
                        </tr>
                        <tr>
                            <td><strong>cell_subtype_or_state</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>cell_class</strong></td>
                            <td>neuronal (principal excitatory neurons of entorhinal/parahippocampal cortex implied)</td>
                        </tr>
                        <tr>
                            <td><strong>markers_or_genes</strong></td>
                            <td>Enriched in healthy MTL: mitochondrial proteins (e.g., MT-ATP8, MT-CYB, MT-ND1, MT-ND4), many ribosomal proteins (RPL17, RPL27A, RPL36, RPL38, RPS4X, etc.), long-term potentiation related proteins; APOE protein higher in MTL.</td>
                        </tr>
                        <tr>
                            <td><strong>brain_region_and_layer</strong></td>
                            <td>Entorhinal cortex and parahippocampal cortex (MTL) — regions affected early in Braak staging (B/B I–II early involvement).</td>
                        </tr>
                        <tr>
                            <td><strong>species_or_model</strong></td>
                            <td>Human postmortem tissue (controls and AD cases), region-to-region comparison in healthy controls and disease progression comparisons</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_or_braak</strong></td>
                            <td>Vulnerability discussed with respect to early B/B stages (I–III) where MTL shows tau pathology first, and comparative late stages (IV–VI) for neocortex.</td>
                        </tr>
                        <tr>
                            <td><strong>susceptibility_label</strong></td>
                            <td>susceptible (MTL neurons argued to be more vulnerable)</td>
                        </tr>
                        <tr>
                            <td><strong>measurement_type</strong></td>
                            <td>Bulk label-free LC-MS/MS proteomics comparing brain regions in controls and changes in AD progression; KEGG/GO enrichment analyses</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_change</strong></td>
                            <td>In control tissue 648 proteins differ between regions; 410 proteins higher in MTL (MTL-up). Among MTL-up: 79 mitochondrial proteins (19.27%), 16 ribosomal proteins and 10 proteasome-complex proteins. During AD many of these MTL-enriched proteins are almost exclusively down-regulated in the MTL during progression. DEPs during progression: EC 248, PHC 278 — highest numbers in early-affected regions.</td>
                        </tr>
                        <tr>
                            <td><strong>pathology_measured</strong></td>
                            <td>Braak/Braak tau staging (regions classified as 'early-affected' MTL vs 'late-affected' neocortex); Aβ measured by PRM increased in AD across regions.</td>
                        </tr>
                        <tr>
                            <td><strong>associations_with_pathology</strong></td>
                            <td>Authors propose that the high baseline metabolic/translation/proteostasis activity in MTL may predispose to earlier impairment with AD triggers; KEGG Alzheimer's disease pathway enriched among proteins overexpressed in MTL (22 proteins, p = 1.61e-7). No direct per-donor correlation stats between these MTL signatures and tangle density are provided in the paper.</td>
                        </tr>
                        <tr>
                            <td><strong>spatial_or_proximity_context</strong></td>
                            <td>Regional (MTL vs neocortex) proteomic differences; microdissected micropunches but no laminar or plaque proximity data.</td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_hypothesis</strong></td>
                            <td>MTL vulnerability hypothesized to arise from (1) higher baseline energy demand and proteostasis load (mitochondria, translation, proteasome), (2) higher APOE protein level in MTL potentially modulating APP/Aβ/tau biology, and (3) early impairment of oxidative phosphorylation and translation in MTL during AD progression leading to neuronal dysfunction and vulnerability.</td>
                        </tr>
                        <tr>
                            <td><strong>ad_gwas_gene_enrichment</strong></td>
                            <td>APOE identified as higher in MTL; AD KEGG pathway enriched in MTL-up proteins (22 proteins, p=1.61e-7). A set of 27 DEPs overlaps AD risk loci overall (no region-specific GWAS enrichment statistic provided).</td>
                        </tr>
                        <tr>
                            <td><strong>perturbation_or_causal_evidence</strong></td>
                            <td>This paper is observational; authors cite external perturbation evidence linking APOE isoforms to tau toxicity (Shi et al., 2017) and APOE to APP transcription (Huang et al., 2017), and studies where energy deprivation increases BACE1 translation and Aβ (O'Connor et al., 2008) supporting mechanistic plausibility.</td>
                        </tr>
                        <tr>
                            <td><strong>modifiers_and_risk_factors</strong></td>
                            <td>APOE genotype discussed as a likely modifier (ε4 increases risk and mediates tau effects); cohort was mostly ε3 homozygotes so limited isoform analysis; age and sex effects were adjusted by removing associated proteins.</td>
                        </tr>
                        <tr>
                            <td><strong>comorbid_pathologies</strong></td>
                            <td>Study used pure AD cases without significant co-pathologies; thus conclusions about MTL vulnerability pertain to AD-only pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>comparisons_to_other_cell_types</strong></td>
                            <td>The MTL proteomic signature (high mitochondria/translation/proteasome) contrasts with neocortex which had higher expression of spliceosome and integrin pathway proteins; neuronal/proteostasis signatures in MTL decline during AD while astrocytic markers increase.</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_or_null_findings</strong></td>
                            <td>Although APOE protein is higher in MTL, statistical significance varied by pairwise comparison (not uniformly significant across all region comparisons) and PRM confirmed some but not all region differences; authors caution further study is needed.</td>
                        </tr>
                        <tr>
                            <td><strong>replication_or_cross_cohort_validation</strong></td>
                            <td>Region-differential signatures and many DEPs show overlap with two other proteomic AD studies (Hondius et al., 2016; Seyfried et al., 2017); APOE region differences were confirmed in PRM for some comparisons (both MTL regions vs FC in PRM dataset).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_and_counts</strong></td>
                            <td>103 samples total; control-region comparison produced 648 DEPs between the four regions (410 proteins higher in MTL cluster 'MTL-up'); MTL DEPs during progression: EC 248, PHC 278.</td>
                        </tr>
                        <tr>
                            <td><strong>dataset_or_platform</strong></td>
                            <td>Discovery LC-MS/MS on Thermo Q Exactive (DDA); PRM on Q Exactive HF-X; GO/KEGG enrichment analyses (DAVID, String); data accession PXD010138.</td>
                        </tr>
                        <tr>
                            <td><strong>functional_impact</strong></td>
                            <td>Authors propose that MTL high metabolic and proteostasis baseline makes these neurons susceptible to early AD triggers, with downstream consequences including impaired oxidative phosphorylation, decreased translation and synaptic dysfunction — processes that likely underlie memory deficits.</td>
                        </tr>
                        <tr>
                            <td><strong>key_evidence_snippet</strong></td>
                            <td>"...a distinct proteomic signature was found between MTL and neocortex in healthy subjects that might be related to AD vulnerability... Several overrepresented pathways in the MTL-up cluster have already known link to AD, such as energy production (oxidative phosphorylation), protein translation, proteasome..."</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease", 'publication_date_yy_mm': '2019-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Profiling the human hippocampal proteome at all pathologic stages of Alzheimer's disease <em>(Rating: 2)</em></li>
                <li>A multi-network approach identifies protein-specific co-expression in asymptomatic and symptomatic Alzheimer's disease <em>(Rating: 2)</em></li>
                <li>Pathological tau promotes neuronal damage by impairing ribosomal function and decreasing protein synthesis <em>(Rating: 2)</em></li>
                <li>ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy <em>(Rating: 2)</em></li>
                <li>Synapse loss and microglial activation precede tangles in a P301S Tauopathy mouse model <em>(Rating: 1)</em></li>
                <li>ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and Aβ secretion <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>